MK-677 Reconstitution Chart (Every Vial Size)

Core Reconstitution Dynamics for MK-677 Research Compounds

MK-677 (Ibutamoren mesylate) is a non-peptidic, long-acting agonist of the growth hormone secretagogue receptor (GHS-R1a). In preclinical research, MK-677 is evaluated for its ability to mimic the endogenous GH-releasing activity of ghrelin, stimulating sustained growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion without acutely elevating baseline cortisol or prolactin. Achieving accurate concentration metrics during in vitro preparation is critical for generating reproducible laboratory data.

When handling raw powder or lyophilized preparations of MK-677, researchers must account for chemical solubility, final target concentrations, and precise volumetric measurements. While PX1 Research offers pre-formulated solid dose formats such as MK-677 Capsules 12.5mg for standardized lab evaluation, liquid assay preparations require meticulous reconstitution calculations. This guide provides exact volumetric parameters for calculating milligram-per-milliliter concentrations across all standard laboratory vial sizes.

Mathematical Foundation: The Reconstitution Formula

Calculating the final concentration of a reconstituted MK-677 solution relies on a straightforward linear equation. Establishing precise volumetric ratios ensures that aliquots delivered to cell cultures or analytical instrumentation remain uniform across assay replicates.

The primary concentration formula is defined as: Concentration (mg/mL) = Total Compound Mass (mg) / Diluent Volume (mL). To determine the absolute mass contained within a specific laboratory draw (for instance, a standard 0.1 mL volumetric micro-aliquot), researchers utilize the secondary equation: Content per 0.1 mL (mg) = Concentration (mg/mL) x 0.1 mL. For digital verification of complex dilution protocols, scientists can utilize our interactive reconstitution calculator to eliminate manual volumetric errors.

Comprehensive MK-677 Reconstitution Chart

The following reference matrix outlines the resulting solution concentration (mg/mL) and corresponding per-0.1 mL active mass for standard laboratory vial quantities (10 mg, 25 mg, 50 mg, and 100 mg) across common diluent reconstitution volumes (1 mL to 10 mL).

Vial Mass: 10 mg | Diluent: 1.0 mL | Final Concentration: 10.0 mg/mL | Mass per 0.1 mL: 1.00 mg Vial Mass: 10 mg | Diluent: 2.0 mL | Final Concentration: 5.0 mg/mL | Mass per 0.1 mL: 0.50 mg Vial Mass: 10 mg | Diluent: 5.0 mL | Final Concentration: 2.0 mg/mL | Mass per 0.1 mL: 0.20 mg Vial Mass: 25 mg | Diluent: 1.0 mL | Final Concentration: 25.0 mg/mL | Mass per 0.1 mL: 2.50 mg Vial Mass: 25 mg | Diluent: 2.5 mL | Final Concentration: 10.0 mg/mL | Mass per 0.1 mL: 1.00 mg Vial Mass: 25 mg | Diluent: 5.0 mL | Final Concentration: 5.0 mg/mL | Mass per 0.1 mL: 0.50 mg Vial Mass: 50 mg | Diluent: 2.0 mL | Final Concentration: 25.0 mg/mL | Mass per 0.1 mL: 2.50 mg Vial Mass: 50 mg | Diluent: 5.0 mL | Final Concentration: 10.0 mg/mL | Mass per 0.1 mL: 1.00 mg Vial Mass: 50 mg | Diluent: 10.0 mL | Final Concentration: 5.0 mg/mL | Mass per 0.1 mL: 0.50 mg Vial Mass: 100 mg | Diluent: 5.0 mL | Final Concentration: 20.0 mg/mL | Mass per 0.1 mL: 2.00 mg Vial Mass: 100 mg | Diluent: 10.0 mL | Final Concentration: 10.0 mg/mL | Mass per 0.1 mL: 1.00 mg

Researchers exploring our complete catalog of analytical standards and research compounds can browse all peptides and small molecules to compare solubility parameters and reagent specifications.

Step-by-Step Worked Reconstitution Examples

Example 1: Standard Concentration Protocol (25 mg Vial with 5 mL Solvent). A researcher intends to reconstitute a 25 mg vial of MK-677 for cell culture medium dosing. Step 1: Using aseptic laboratory technique, draw 5.0 mL of designated solvent into a sterile pipette or syringe. Step 2: Slowly introduce the solvent along the inner glass wall of the vial. Step 3: Gently swirl (do not vortex excessively) until the powder is fully dissolved. Calculation: Concentration = 25 mg / 5.0 mL = 5.0 mg/mL. Each 0.1 mL sample withdrawn yields exactly 0.5 mg (500 mcg) of active compound.

Example 2: Concentrated Stock Solution (50 mg Vial with 2 mL Solvent). For high-throughput automated dispensing where low liquid volume is required, a lab reconstitutes 50 mg of MK-677 in 2.0 mL of solvent. Step 1: Add 2.0 mL of suitable solvent to the 50 mg vial. Step 2: Allow complete dissolution. Calculation: Concentration = 50 mg / 2.0 mL = 25.0 mg/mL. A 0.1 mL aliquot from this stock solution delivers 2.5 mg of active reagent.

Solubility Profiles and Solvent Selection for In Vitro Assays

Unlike classic hydrophilic peptides, MK-677 (Ibutamoren mesylate) possesses distinct chemical solubility characteristics. It displays high solubility in dimethyl sulfoxide (DMSO), ethanol, and polyethylene glycol (PEG400), while displaying moderate solubility in aqueous solutions depending on pH and salt concentration.

For aqueous in vitro assays, researchers often prepare a concentrated primary stock solution in sterile DMSO or ethanol before diluting into culture media. If preparing an aqueous laboratory solution directly, sterile bacteriostatic water or phosphate-buffered saline (PBS) may be utilized, provided gentle warming (up to 37°C) and sonication are applied if minor precipitation occurs. Solvents must be chosen based on cell line tolerance to ensure carrier solutions do not alter baseline cellular viability.

Pharmacological Class Comparison: Oral GHS vs. Injectable Peptides

In preclinical endocrine research, MK-677 is evaluated alongside peptide-based somatotropic secretagogues. While MK-677 operates as a non-peptide GHS-R1a agonist with a prolonged half-life, traditional peptide research compounds interact with pituitary receptors via distinct structural mechanisms.

For example, preclinical models frequently compare MK-677 against peptide secretagogues such as Ipamorelin, CJC-1295 No DAC, and GHRP-6. While peptide secretagogues typically require daily aqueous reconstitution due to rapid enzymatic degradation, MK-677 maintains chemical stability across broader non-aqueous solvent matrices. Understanding these structural differences helps researchers select the optimal secretagogue model for specific in vitro assays.

Laboratory Storage, Handling, and Stability Protocols

To preserve structural integrity and prevent degradation, lyophilized MK-677 powder should be stored in a dry, dark environment at -20°C. Under these conditions, the compound remains stable for up to 24 months. Desiccation precautions should be taken to prevent moisture absorption when removing vials from sub-zero storage.

Once reconstituted in liquid solution, stability depends heavily on the solvent vehicle. DMSO and ethanol stock solutions stored at -20°C remain stable for several months, whereas aqueous preparations should be stored at 2°C to 8°C and utilized within defined experimental windows to prevent hydrolytic decay. Exposure to direct ultraviolet light and elevated temperatures should be strictly avoided.

Quality Assurance: HPLC, MS, and COA Verification

Inaccurate mass specifications or chemical impurities directly undermine experimental validity. PX1 Research subjects every lot of MK-677 and related research compounds to rigorous third-party analytical testing, including High-Performance Liquid Chromatography (HPLC) for purity determination and Mass Spectrometry (MS) for structural identification.

All catalog compounds manufactured in our USA facilities meet or exceed 99% purity thresholds with certified endotoxin testing (<0.01 EU/mg). Researchers can review lot-specific analytical reports directly by accessing our batch documentation on the COA transparency portal. Bulk research institutions requiring large-scale allocations can also establish dedicated accounts via our wholesale portal.